Bahl & Gaynor’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.38M Sell
39,051
-100
-0.3% -$9.58K 0.02% 185
2025
Q4
$3.76M Sell
39,151
-2,454
-6% -$238K 0.02% 185
2025
Q3
$3.96M Sell
41,605
-6,404
-13% -$589K 0.02% 185
2025
Q2
$4.18M Sell
48,009
-580
-1% -$49.2K 0.02% 180
2025
Q1
$4.37M Sell
48,589
-857
-2% -$76.7K 0.02% 178
2024
Q4
$3.95M Sell
49,446
-4,426
-8% -$383K 0.02% 180
2024
Q3
$4.85M Sell
53,872
-2,273
-4% -$191K 0.03% 177
2024
Q2
$4.42M Sell
56,145
-16,963
-23% -$1.39M 0.02% 176
2024
Q1
$6.37M Sell
73,108
-61,008
-45% -$5.21M 0.04% 154
2023
Q4
$11M Sell
134,116
-646,082
-83% -$49.2M 0.07% 125
2023
Q3
$61.1M Sell
780,198
-317,344
-29% -$26.6M 0.39% 61
2023
Q2
$96.7M Sell
1,097,542
-383,807
-26% -$33M 0.59% 51
2023
Q1
$119M Sell
1,481,349
-612,887
-29% -$50M 0.64% 50
2022
Q4
$163M Sell
2,094,236
-418,716
-17% -$33.9M 1.02% 34
2022
Q3
$203M Buy
2,512,952
+25,161
+1% +$2.26M 1.34% 27
2022
Q2
$223M Buy
2,487,791
+788,483
+46% +$79.9M 1.47% 25
2022
Q1
$189M Sell
1,699,308
-744,248
-30% -$78.6M 1.39% 28
2021
Q4
$253M Buy
2,443,556
+245,187
+11% +$28.4M 1.41% 26
2021
Q3
$276M Buy
2,198,369
+192,304
+10% +$24.9M 1.69% 21
2021
Q2
$249M Sell
2,006,065
-28,172
-1% -$3.54M 1.52% 27
2021
Q1
$240M Sell
2,034,237
-56,958
-3% -$6.68M 1.52% 26
2020
Q4
$245M Sell
2,091,195
-56,417
-3% -$6.21M 1.56% 24
2020
Q3
$223M Sell
2,147,612
-3,674
-0.2% -$369K 1.58% 26
2020
Q2
$197M Buy
2,151,286
+21,188
+1% +$2.03M 1.48% 29
2020
Q1
$192M Sell
2,130,098
-35,337
-2% -$3.76M 1.67% 21
2019
Q4
$246M Buy
2,165,435
+21,326
+1% +$2.34M 1.7% 19
2019
Q3
$233M Buy
2,144,109
+120,595
+6% +$12.6M 1.68% 19
2019
Q2
$197M Buy
2,023,514
+47,716
+2% +$4.36M 1.46% 23
2019
Q1
$180M Buy
1,975,798
+38,305
+2% +$3.43M 1.65% 23
2018
Q4
$176M Buy
1,937,493
+639,768
+49% +$59.8M 1.88% 18
2018
Q3
$128M Sell
1,297,725
-641,545
-33% -$59.3M 1.64% 19
2018
Q2
$166M Buy
1,939,270
+82,336
+4% +$6.88M 1.74% 19
2018
Q1
$149M Sell
1,856,934
-89,096
-5% -$7.35M 1.64% 21
2017
Q4
$157M Buy
1,946,030
+154,380
+9% +$12.4M 1.62% 24
2017
Q3
$139M Buy
1,791,650
+16,239
+0.9% +$1.35M 1.53% 27
2017
Q2
$158M Buy
1,775,411
+542,061
+44% +$45.7M 1.8% 16
2017
Q1
$99.4M Sell
1,233,350
-113,629
-8% -$8.88M 1.14% 32
2016
Q4
$95.9M Sell
1,346,979
-81,505
-6% -$6.4M 1.17% 33
2016
Q3
$123M Buy
1,428,484
+116,971
+9% +$10.2M 1.49% 27
2016
Q2
$114M Buy
1,311,513
+650,636
+98% +$52.6M 1.48% 25
2016
Q1
$49.6M Buy
660,877
+342,187
+107% +$25.8M 0.66% 50
2015
Q4
$24.5M Sell
318,690
-15,591
-5% -$1.17M 0.34% 72
2015
Q3
$22.4M Buy
334,281
+71,992
+27% +$5.3M 0.32% 82
2015
Q2
$19.4M Buy
262,289
+2,783
+1% +$213K 0.26% 83
2015
Q1
$20.2M Buy
259,506
+10,474
+4% +$794K 0.27% 81
2014
Q4
$18M Buy
249,032
+31,213
+14% +$2.17M 0.25% 84
2014
Q3
$13.5M Buy
217,819
+9,497
+5% +$604K 0.2% 85
2014
Q2
$13.3M Buy
208,322
+181,775
+685% +$11M 0.2% 87
2014
Q1
$1.63M Sell
26,547
-2,467
-9% -$144K 0.03% 181
2013
Q4
$1.67M Buy
29,014
+7,800
+37% +$442K 0.03% 178
2013
Q3
$1.13M Sell
21,214
-1,420
-6% -$76.4K 0.02% 185
2013
Q2
$1.17M Buy
+22,634
New +$1.12M 0.02% 179

Other funds holding MDT

Bahl & Gaynor's MDT Position: Q1 2026 in Review

Bahl & Gaynor reduced its Medtronic (MDT) stake by 0.26% in Q1 2026, selling an estimated $9.58K and leaving 39,051 shares worth $3.38M. The position accounts for 0.02% of the portfolio, ranked #185.

Bahl & Gaynor first reported a position in MDT in Q2 2013 and has held it in 52 quarters since. The position peaked at $276M in Q3 2021. 2,229 funds tracked by Wall St. Rank hold MDT as of Q1 2026.

  • Bahl & Gaynor held 39,051 shares of Medtronic worth $3.38M as of Q1 2026.
  • Bahl & Gaynor sold 100 Medtronic shares in Q1 2026, an estimated $9.58K.
  • Medtronic made up 0.02% of Bahl & Gaynor's portfolio in Q1 2026, its #185 holding.
  • Bahl & Gaynor first reported a position in Medtronic in Q2 2013 and has held it in 52 quarters since.
  • Bahl & Gaynor's Medtronic position peaked at $276M in Q3 2021.
  • 2,229 funds tracked by Wall St. Rank held Medtronic as of Q1 2026.

Based on Bahl & Gaynor's 13F filing for Q1 2026, filed 7 May 2026.